Skip to content
type1.science
Phase 2Not yet recruitingNCT07421518

Ketone monitoring to reduce DKA risk during adjunct SGLT2 inhibition

AdventHealth study of a continuous-ketone-monitoring education plan for people with type 1 diabetes using sotagliflozin, including insulin-withdrawal testing to study ketone risk mitigation.

Primary endpoints

  • Ketone events with beta-hydroxybutyrate above 1.5 mmol/L over 6 months

Results so far

No results posted yet.